Redx Pharma plc Result of AGM and Directorate change (8923Q)

TIDMREDX

RNS Number : 8923Q

Redx Pharma plc

02 March 2021

REDX PHARMA PLC

("Redx" or "the Company")

Result of Annual General Meeting and Directorate change

Alderley Park, 2 March 2021 Redx Pharma (AIM:REDX), the drug discovery and development Company focused on oncology and fibrosis, today announces that its Annual General Meeting was held at 11.00 am on 2 March 2021, with all resolutions passed by substantial majorities.

The table below sets out the details of the votes put to shareholders

 
  Resolution    Resolution              Number       % of votes        Number        % of        % of    Total 
     numbe       name                 of votes            for &      of votes       votes       votes    votes 
                                         for &    discretionary       against     against     witheld    cast 
                                 discretionary                                                           (including 
                                                                                                         withheld) 
                Receive the 
                Company's 
                annual 
      1         accounts           247,031,884           94.79%    13,571,429       5.21%       0.00%    260,604,013 
              ---------------  ---------------  ---------------  ------------  ----------  ----------  --------------- 
                Re-appoint 
                RSM as 
      2         auditors           260,597,840             100%           200       0.00%       0.00%    260,604,013 
              ---------------  ---------------  ---------------  ------------  ----------  ----------  --------------- 
                Elect Sarah 
                Gordon Wild 
      3         as a director      260,597,840             100%           200       0.00%       0.00%    260,604,013 
              ---------------  ---------------  ---------------  ------------  ----------  ----------  --------------- 
                Elect Dr 
                Thomas Burt 
      4         as a director      260,597,840             100%           200       0.00%       0.00%    260,604,013 
              ---------------  ---------------  ---------------  ------------  ----------  ----------  --------------- 
                Re-elect 
                Lisa Anson 
      5         as a director      260,603,513             100%             0       0.00%       0.00%    260,604,013 
              ---------------  ---------------  ---------------  ------------  ----------  ----------  --------------- 
                Re-elect 
                Dr Bernd 
                Kirschbaum 
      6         as a director      260,598,040             100%             0       0.00%       0.00%    260,604,013 
              ---------------  ---------------  ---------------  ------------  ----------  ----------  --------------- 
                Re-elect 
                Peter 
                Presland 
      7         as a director      260,603,513             100%             0       0.00%       0.00%    260,604,013 
              ---------------  ---------------  ---------------  ------------  ----------  ----------  --------------- 
                Authorise 
                the directors 
                to allot 
      8         shares             260,594,551             100%         1,686       0.00%       0.00%    260,604,013 
              ---------------  ---------------  ---------------  ------------  ----------  ----------  --------------- 
                Disapply 
                 pre-emption 
      9          rights            260,594,551             100%         2,389       0.00%       0.00%    260,604,013 
              ---------------  ---------------  ---------------  ------------  ----------  ----------  --------------- 
 

The Chairman, Iain Ross provided the following update:

"As the Company continues to progress its pipeline and expand its operations, the Board has reviewed its composition and that of the executive leadership team. As a result, a search for a US based Chief Financial Officer has been initiated. James Mead will continue in his role as Chief Financial Officer until a new appointment has been made at which point Dr Mead will assume the role of Chief Operating Officer. In conjunction with these changes, Dr Mead will step down from the Board with immediate effect and will cease to be a Director of the Company. Going forward, the Board will therefore consist of five non-executive directors and one executive director, the CEO. Finally on a personal basis I would like to thank James for his contribution to the Board over the last two years, and his ongoing commitment as a member of the executive management team going forward."

 
  For further information, please contact: 
 
  Redx Pharma Plc                                T: [phone] 
                                                  918 
  Iain Ross, Chairman 
   Lisa Anson, Chief Executive 
   James Mead, Chief Financial Officer 
 
  SPARK Advisory Partners (Nominated Adviser)     T: [phone] 
                                                   3550 
  Matt Davis/Adam Dawes 
 
  WG Partners LLP (Broker)                       T: [phone] 
                                                  9330 
  Claes Spång/Chris Lee/David Wilson 
 
 
  FTI Consulting                                 T: [phone] 
                                                  1000 
  Simon Conway/Ciara Martin 
 
 

About Redx Pharma Plc

Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease, aiming to progress them to clinical proof of concept. Redx's lead oncology asset, RXC004, is currently in a phase 1 study in patients with advanced malignancies with top line data expected in H1 2021 and the Company's selective ROCK2 inhibitor, RXC007, is expected to enter a phase 1 clinical study in H1 2021.

The Company's core capability of converting medicinal chemistry insights into differentiated and commercially attractive small molecule drug candidates against clinically validated targets has been recognized by others. Over the last three years the company has completed four major preclinical stage deals with AstraZeneca, Jazz Pharmaceuticals and Loxo Oncology (now Eli Lilly).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGUUOURANUORAR

(END) Dow Jones Newswires

March 02, 2021 07:38 ET (12:38 GMT)